focus -WSS

focus

author：knowledge 2025-09-03 14:42:31 - browse：264

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Illumina board agrees to spin off Grail, as divestment plans proceed

Wikipedia

WSS

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Finland to offer bird flu vaccine to select groups of people, a possible global first

Sanofi seeks simpler, safer CRISPR sickle cell cure

How CO2 helps viruses stay alive longer in the air

Stopping antidepressants leads to symptoms for 1 in 6 patients

Sanofi seeks simpler, safer CRISPR sickle cell cure

knowledge

focus

focus

Hollywood unions extend contract negotiations for actors

At Orexo, a ‘turning point’ for everything but digital health

Cancer drug shortages should be causing more outrage

A public scorecard can help hold safety

Medicare proposal to cover medical devices draws a mixed reaction

Structure Therapeutics oral GLP

Bright Health sells Medicare Advantage business to Molina

Listen: Wegovy in the brain & pivotal Alzheimer's data

Guidelines to prevent youth baseball injuries need more muscle

Sanofi seeks simpler, safer CRISPR sickle cell cure

focus

Take antibiotics after sex, CDC recommends for certain risk groups

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

BD to buy Edwards patient monitoring unit for $4.2 billion

Stopping antidepressants leads to symptoms for 1 in 6 patients

Sanofi seeks simpler, safer CRISPR sickle cell cure

Key House panel plots a new health care package

knowledge

Wikipedia

entertainment

leisure time